These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 9155621)

  • 21. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of antitachycardia pacing with defibrillation.
    Lüderitz B
    Pacing Clin Electrophysiol; 1991 Feb; 14(2 Pt 2):312-6. PubMed ID: 1706844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antitachycardia pacing in patients with implanted cardioverter defibrillators].
    Ardashev AV; Dzhandzhgava AO; Zheliakov EG
    Kardiologiia; 2011; 51(1):65-73. PubMed ID: 21626805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications.
    Link MS; Bockstall K; Weinstock J; Alsheikh-Ali AA; Semsarian C; Estes NAM; Spirito P; Haas TS; Rowin EJ; Maron MS; Maron BJ
    J Cardiovasc Electrophysiol; 2017 May; 28(5):531-537. PubMed ID: 28240435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel low-energy electrotherapy that terminates ventricular tachycardia with lower energy than a biphasic shock when antitachycardia pacing fails.
    Janardhan AH; Li W; Fedorov VV; Yeung M; Wallendorf MJ; Schuessler RB; Efimov IR
    J Am Coll Cardiol; 2012 Dec; 60(23):2393-8. PubMed ID: 23141483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transtelephonic monitoring and transmission of stored arrhythmia detection and therapy data from an implantable cardioverter defibrillator.
    Fetter JG; Stanton MS; Benditt DG; Trusty J; Collins J
    Pacing Clin Electrophysiol; 1995 Aug; 18(8):1531-9. PubMed ID: 7479174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
    Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
    Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with prophylactic cardioverter-defibrillator therapy.
    Grimm W; Plachta E; Maisch B
    Pacing Clin Electrophysiol; 2006 Jul; 29(7):759-64. PubMed ID: 16884513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
    Bunch TJ; Mahapatra S; Murdock D; Molden J; Weiss JP; May HT; Bair TL; Mader KM; Crandall BG; Day JD; Osborn JS; Muhlestein JB; Lappe DL; Anderson JL
    Pacing Clin Electrophysiol; 2011 Dec; 34(12):1600-6. PubMed ID: 21895727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Case report and review about radiofrequency catheter ablation in a patient with dilated cardiomyopathy and an implantable cardioverter defibrillator].
    Lepillier A; Paziaud O; Lascault G; Copie X; Piot O
    Ann Cardiol Angeiol (Paris); 2009 Feb; 58(1):34-9. PubMed ID: 18667195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Death due to an implantable cardioverter defibrillator.
    Messali A; Thomas O; Chauvin M; Coumel P; Leenhardt A
    J Cardiovasc Electrophysiol; 2004 Aug; 15(8):953-6. PubMed ID: 15333095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy.
    Cha YM; Gersh BJ; Maron BJ; Boriani G; Spirito P; Hodge DO; Weivoda PL; Trusty JM; Friedman PA; Hammill SC; Rea RF; Shen WK
    J Cardiovasc Electrophysiol; 2007 May; 18(5):483-7. PubMed ID: 17343723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programming antitachycardia pacing for primary prevention in patients with implantable cardioverter defibrillators: results from the PROVE trial.
    Saeed M; Neason CG; Razavi M; Chandiramani S; Alonso J; Natarajan S; Ip JH; Peress DF; Ramadas S; Massumi A
    J Cardiovasc Electrophysiol; 2010 Dec; 21(12):1349-54. PubMed ID: 20561107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arrhythmia rate distribution and tachyarrhythmia therapy in an ICD population: results from the INTRINSIC RV trial.
    Sullivan RM; Russo AM; Berg KC; Stolen KQ; Seth M; Perschbacher D; Day JD; Olshansky B
    Heart Rhythm; 2012 Mar; 9(3):351-8. PubMed ID: 22016074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of shock timing on efficacy and safety of internal cardioversion for ventricular tachycardia.
    Li HG; Yee R; Mehra R; DeGroot P; Klein GJ; Zardini M; Thakur RK; Morillo CA
    J Am Coll Cardiol; 1994 Sep; 24(3):703-8. PubMed ID: 8077542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of intrinsic antitachycardia pacing for ventricular tachycardia refractory to conventional burst pacing: A case series.
    Kamakura T; Ueda N; Wada M; Ishibashi K; Kusano K
    J Cardiovasc Electrophysiol; 2023 Jan; 34(1):225-228. PubMed ID: 36511471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial.
    Al-Khatib SM; Daubert JP; Anstrom KJ; Daoud EG; Gonzalez M; Saba S; Jackson KP; Reece T; Gu J; Pokorney SD; Granger CB; Hess PL; Mark DB; Stevenson WG
    J Cardiovasc Electrophysiol; 2015 Feb; 26(2):151-7. PubMed ID: 25332150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardioversion, defibrillation, and overdrive pacing of ventricular arrhythmias: the effect of moricizine in dogs with sustained monomorphic ventricular tachycardia.
    Avitall B; Hare J; Zander G; Lessila C; Dhala A; Deshpande S; Jazayeri M; Sra J; Akhtar M
    Pacing Clin Electrophysiol; 1993 Nov; 16(11):2092-7. PubMed ID: 7505920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biventricular implantable cardioverter defibrillator and inappropriate shocks.
    Srivathsan K; Bazzell JL; Lee RW
    J Cardiovasc Electrophysiol; 2003 Jan; 14(1):88-9. PubMed ID: 12625617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.